ocs-02 – IR Zen

August 23, 2022 by: acn

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

LAUSANNE, Switzerland, Aug 23, 2022 – (ACN Newswire via SEAPRWire.com) – Oculis S.A., (‘Oculis’) a global ophthalmology company developing life-changing treatments to save sight and …

More ...